- Conditions
- Hearing Loss
- Interventions
- Electric Acoustic System
- Device
- Lead sponsor
- Med-El Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 14
- States / cities
- Stanford, California • Miami, Florida • Indianapolis, Indiana + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2305–2328
of 8,629
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Puberty, Precocious
- Interventions
- Leuprolide acetate 11.25 mg, Leuprolide acetate 30 mg
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Long Beach, California • Los Angeles, California + 16 more
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 11
- States / cities
- Galesburg, Illinois • Bloomington, Indiana • Evansville, Indiana + 6 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Sorafenib (Nexavar, BAY43-9006)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 2,567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 312
- States / cities
- Bessemer, Alabama • Cullman, Alabama • Mobile, Alabama + 255 more
- Conditions
- Von Willebrand Disease (VWD)
- Interventions
- rVWF, rFVIII
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Aurora, Colorado • Gainesville, Florida + 5 more
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2001
- U.S. locations
- 3
- States / cities
- San Francisco, California • Indianapolis, Indiana
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Nipent, Cytoxan, Rituxan
- Drug
- Lead sponsor
- East Valley Hematology and Oncology Medical Group
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 52
- States / cities
- Muscle Shoals, Alabama • Burbank, California • Concord, California + 44 more
- Conditions
- Multiple Sclerosis
- Interventions
- Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California + 13 more
- Conditions
- Chronic Granulomatous Disease (CGD)
- Interventions
- Not listed
- Lead sponsor
- Ensoma
- Industry
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 50
- States / cities
- Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
- Conditions
- Cutaneous Lupus Erythematosus
- Interventions
- CC-11050, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 19
- States / cities
- Rogers, Arkansas • Los Angeles, California • San Diego, California + 15 more
- Conditions
- Diabetic Macular Edema
- Interventions
- intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group
- Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 54
- States / cities
- Campbell, California • Glendale, California • Loma Linda, California + 46 more
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Placebo, secukinumab (AIN457), etanercept
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Greg Durm, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- guadecitabine, Treatment Choice (TC)
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 11 more
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Quetiapine or Risperidone + Aripiprazole, Quetiapine or Risperidone + placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 48
- States / cities
- Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more
- Conditions
- Dermatitis, Atopic
- Interventions
- LY3471851, Placebo
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 20
- States / cities
- North Little Rock, Arkansas • Encinitas, California • Fremont, California + 17 more
- Conditions
- Methemoglobinemia, Acquired, Methemoglobinemia
- Interventions
- Methylene Blue
- Drug
- Lead sponsor
- Hospital Quality Foundation
- Other
- Eligibility
- Not listed
- Enrollment
- 24 participants
- Timeline
- 2018 – 2021
- U.S. locations
- 32
- States / cities
- Los Angeles, California • Sacramento, California • Bridgeport, Connecticut + 27 more
- Conditions
- Haemophilia A, Haemophilia A With Inhibitors
- Interventions
- Mim8
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more
- Conditions
- Anxiety Disorders
- Interventions
- AZD7325, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 725 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Arcadia, California + 49 more
- Conditions
- Hepatitis C
- Interventions
- Daclatasvir, Asunaprevir, BMS-791325, Ribavirin, Placebo matching Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 26
- States / cities
- La Jolla, California • San Diego, California • San Francisco, California + 22 more
- Conditions
- Hepatitis
- Interventions
- Larsucosterol, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more
- Conditions
- Carotid Artery Disease
- Interventions
- Not listed
- Lead sponsor
- Silk Road Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 692 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 41
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 34 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- GB-102, Aflibercept
- Drug
- Lead sponsor
- Graybug Vision
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more
- Conditions
- Myopia, Progressive
- Interventions
- OT-101 Ophthalmic Solution, Vehicle
- Drug
- Lead sponsor
- Ocumension (Hong Kong) Limited
- Other
- Eligibility
- 3 Years to 15 Years
- Enrollment
- 678 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 15
- States / cities
- Colorado Springs, Colorado • Fort Collins, Colorado • Gainesville, Florida + 12 more